Roth Capital Reiterates Buy On MEI Pharma Shares, $20 PT
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on MEI Pharma (NASDAQ:MEIP) with a price target of $20.00.
Pantginis noted, “We expect MEIP visibility to increase strongly as we expect major data catalysts starting at ASH in December. Today the company completed enrollment in a randomized Phase II MDS study and data are expected in 1Q15. We recommend investors own the name ahead of these upcoming data catalysts.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -5.5% and a 44.5% success rate. Pantginis has a -2.0% average return when recommending MEIP, and is ranked #3204 out of 3253 analysts.